Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
48 hedge funds and large institutions have $349M invested in Tourmaline Bio in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 7 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
0.03% less ownership
Funds ownership: 6.29% → 6.26% (-0.03%)
4% less funds holding
Funds holding: 50 → 48 (-2)
8% less capital invested
Capital invested by funds: $379M → $349M (-$29.9M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.41M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.05M |
| 3 |
State Street
Boston,
Massachusetts
|
+$467K |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$255K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$1.25M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$1.06M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$735K |
| 4 |
BlackRock
New York
|
-$565K |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$494K |
TRML Hedge Fund Activity: Q3 2021 in Review
48 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q3 2021, worth a combined $349M — down 7.9% from $379M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRML and 5 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 16 added.
The largest buyer was Sectoral Asset Management, adding an estimated $1.41M. The largest seller was HHLR Advisors, cutting an estimated $1.25M.
- 48 institutional investors held Tourmaline Bio (TRML) as of Q3 2021, down from 50 in Q2 2021.
- Funds reported $349M of Tourmaline Bio stock for Q3 2021, down 7.9% quarter-over-quarter.
- 5 funds opened new Tourmaline Bio positions in Q3 2021 and 7 closed out, a net change of -2 holders.
- The largest Tourmaline Bio buyer in Q3 2021 was Sectoral Asset Management, an estimated $1.41M added.
- The largest Tourmaline Bio seller in Q3 2021 was HHLR Advisors, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2021.